Skip to content
You are now leaving https://www.ionispharma.com to visit

About

Ionis: A force for life

Ionis is THE leading innovator in RNA-targeted therapeutics and was purposely designed to:

  • Create a better, more efficient drug discovery platform
  • Establish a new innovation-centered business model, and
  • Maximize the value of every medicine we create and get it to the people who need it most as quickly and as efficiently as possible

Today we are a sustainably profitable, multi-product company that is delivering transformative breakthroughs for patients… again and again.

A passion to innovate

Ionis is guided by world-class scientists and business leaders whose passion to innovate is matched only by their commitment to deliver transformational medicines to patients who need them.

Brett P. Monia, Ph.D.
Chief Executive Officer
Elizabeth L. Hougen

Brett P. Monia, Ph.D.

Chief Executive Officer

Dr. Monia is the chief executive officer and a founding member of Ionis Pharmaceuticals. His contributions at Ionis include research into the medicinal chemistry and mechanisms of action of RNA-targeting modalities to treat human diseases, most notably antisense-based therapeutic strategies. Dr. Monia has extensive experience across a range of therapeutic areas, including oncology, metabolic disease, inflammation, neurological disease and cardiovascular disease, which have resulted in a broad range of successful clinical achievements and in marketing approvals for new medicines.

Dr. Monia has published more than 200 primary research manuscripts, reviews and book chapters, and is an inventor on more than 100 issued patents. He serves as a senior editor for the journal Nucleic Acid Therapeutics, is on the Board of Directors for Dynacure, and has served as president of the Oligonucleotide Therapeutics Society (OTS). Dr. Monia is also an adjunct professor of biology at San Diego State University where he lectures at the graduate level on pharmacology.

Dr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and B.S. degrees in Molecular Biology and Analytical Chemistry at Stockton State College in Pomona, New Jersey.

Elizabeth L. Hougen
Senior Vice President, Finance and Chief Financial Officer
C. Frank Bennett
Brett P. Monia

Elizabeth L. Hougen

Senior Vice President, Finance and Chief Financial Officer

Ms. Hougen is the senior vice president of Finance and chief financial officer. As a member of the executive leadership team, Ms. Hougen contributes to the execution of strategy, including ensuring Ionis remains well positioned to be a global, multi-product sustainably profitable company. She leads the finance, accounting, tax, treasury, information technology, procurement and facilities functions. Ms. Hougen also contributes to investor relations and corporate communications functions. Ms. Hougen joined Ionis in May 2000 as vice president of finance, and became chief accounting officer in January 2007 and chief financial officer in January 2013.

Ms. Hougen has an extensive finance and business background having held positions of increasing responsibility in numerous public companies, primarily in the life sciences industry, over her more than 25-year career. Prior to joining Ionis, Ms. Hougen was chief financial officer for Molecular Biosystems, Inc., a public biotechnology company.

In recognition of her important contributions to the financial success of Ionis, in 2018 Ms. Hougen was named a CFO of the Year by the San Diego Business Journal. Ms. Hougen received her M.B.A. from the University of San Diego and her B.A. from Franklin and Marshall College.

C. Frank Bennett, Ph.D.
Chief Scientific Officer
Onaiza Cadoret-Manier
Elizabeth L. Hougen

C. Frank Bennett, Ph.D.

Chief Scientific Officer

Dr. Bennett is the chief scientific officer at Ionis Pharmaceuticals and one of the founding members of the company. He is responsible for continuing to advance antisense technology and expanding Ionis drug discovery platform. Dr. Bennett is also the franchise leader for neurological programs at Ionis. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery, pharmacokinetics and medicinal chemistry.

Dr. Bennet is a co-recipient of the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of SPINRAZA® (nusinersen) and the 2018 Hereditary Disease Foundation's (HDF) Leslie Gehry Brenner Prize for Innovation in Science for his leadership and continued commitment to developing antisense therapies for Huntington's disease (HD).

Dr. Bennett has published more than 230 papers in the field of antisense research and development, and he is an inventor on more than 175 issued patents.

Prior to joining Ionis, Dr. Bennett was associate senior investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories (currently, GlaxoSmithKline).

He received his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas and his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico. He performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories.

Dr. Bennett serves on the Advisory Board for the Hereditary Disease Foundation.

Onaiza Cadoret-Manier
Chief Corporate Development and Commercial Officer
Richard S. Geary
C. Frank Bennett

Onaiza Cadoret-Manier

Chief Corporate Development and Commercial Officer

Ms. Cadoret-Manier is the chief corporate development and commercial officer at Ionis Pharmaceuticals. In this role, she serves as a member of Ionis' executive leadership team and is responsible for corporate strategy, business development, and commercial leadership.

Ms. Cadoret-Manier has over 25 years of experience in life sciences, in multiple senior management positions, overseeing strategic planning, business development, and leading sizeable commercial businesses for numerous disease areas for Genentech, Pfizer and Amylin Pharmaceuticals. She has an MBA from the University of Chicago and a bachelor's degree in economics from Queens College.

Richard S. Geary, Ph.D.
Senior Vice President, Development
Patrick R. O’Neil
Onaiza Cadoret-Manier

Richard S. Geary, Ph.D.

Senior Vice President, Development

Dr. Geary is the senior vice president of development at Ionis Pharmaceuticals. He is responsible for preclinical development, clinical development and clinical-stage manufacturing for Ionis’ antisense medicines. Since joining Ionis in 1995, Dr. Geary has been involved in discovery and development including the regulatory submission of more than 40 investigational new drug applications to U.S. and other regulatory agencies. In his position as head of development, Dr. Geary has led four successful antisense medicine late stage development programs through approvals in multiple jurisdictions.

During his tenure at Ionis, he has authored or co-authored 14 book chapters and more than 80 peer-reviewed manuscripts, which form a body of work that fully characterize the pharmacokinetics and metabolism of antisense medicines and the relationship of drug concentrations to activity and safety. Dr. Geary also serves on the Oligonucleotide Therapeutics Society (OTS) Board of Directors and co-leads the publication committee for Nucleic Acid Therapeutics.

Prior to joining Ionis, Dr. Geary was senior research scientist and group leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute. Dr. Geary received his Ph.D. in Biopharmaceutics from the University of Texas, College of Pharmacy, Austin, Texas and his B.S. in Biology from Texas A&M University, College Station, Texas.

 

Patrick R. O’Neil, Esq.
Senior Vice President, Legal, General Counsel and Chief Compliance Officer
Eric E. Swayze
Richard S. Geary

Patrick R. O’Neil, Esq.

Senior Vice President, Legal, General Counsel and Chief Compliance Officer

Mr. O’Neil is the senior vice president of Legal, General Counsel and Chief Compliance Officer of Ionis Pharmaceuticals. He is responsible for managing the legal, patent and GCP QA/QC departments. Mr. O’Neil also serves as Ionis’ corporate secretary. Mr. O’Neil joined Ionis in October 2001.

Prior to joining Ionis, Mr. O’Neil was an associate at Cooley LLP.

Mr. O’Neil received his BS in Business Administration, Finance Concentration from the University of San Francisco and his J.D. at UC Davis School of Law.

 

Eric E. Swayze, Ph.D.
Senior Vice President, Research
Patrick R. O’Neil

Eric E. Swayze, Ph.D.

Senior Vice President, Research

Dr. Swayze is senior vice president of Research at Ionis Pharmaceuticals. He is responsible for leading preclinical antisense drug discovery and antisense technology research.

Previously, Dr. Swayze was vice president of Chemistry and Neuroscience Drug Discovery at Ionis, overseeing the advancement of multiple programs to clinical development. He joined Ionis in 1994 and has contributed to key technology advancements, including Ionis' Generation 2.5 chemistry and Ligand-Conjugated Antisense (LICA) technology.

He is an author on more than 150 scientific manuscripts, several reviews and book chapters, and is an inventor of more than 140 issued US patents. He received his Ph.D. in Organic Chemistry at the University of Michigan under the guidance of Professor Leroy B. Townsend.

Adam Mullick, Ph.D.
VP, Drug Discovery
Anthony Scozzari

Adam Mullick, Ph.D.

VP, Drug Discovery
Anthony Scozzari
VP, DevChem & Mfg
Brian Birchler
Adam Mullick

Anthony Scozzari

VP, DevChem & Mfg
Brian Birchler
VP, Development Ops
Brian Lemay
Anthony Scozzari

Brian Birchler

VP, Development Ops
Brian Lemay
VP, Tax
Charles Asare
Brian Birchler

Brian Lemay

VP, Tax
Charles Asare, M.D., MPH
VP & Head of Drug Safety
Cliff Ford
Brian Lemay

Charles Asare, M.D., MPH

VP & Head of Drug Safety
Cliff Ford
VP, Patents
Daniel Capaldi
Charles Asare

Cliff Ford

VP, Patents
Daniel Capaldi, Ph.D.
VP, Analytical & Process Chemistry
Darren Gonzales
Cliff Ford

Daniel Capaldi, Ph.D.

VP, Analytical & Process Chemistry
Darren Gonzales
Chief Accounting Officer
Dave Ecker
Daniel Capaldi

Darren Gonzales

Chief Accounting Officer
Dave Ecker, Ph.D.
VP, Strategic Innovation
Eugene Schneider
Darren Gonzales

Dave Ecker, Ph.D.

VP, Strategic Innovation
Eugene Schneider, M.D.
VP & Head of Clinical Development
Frank Rigo
Dave Ecker

Eugene Schneider, M.D.

VP & Head of Clinical Development
Frank Rigo, Ph.D.
VP, Drug Discovery
Holly Kordasiewicz
Eugene Schneider

Frank Rigo, Ph.D.

VP, Drug Discovery
Holly Kordasiewicz, Ph.D.
VP, Drug Discovery
Jeffery Engelhardt
Frank Rigo

Holly Kordasiewicz, Ph.D.

VP, Drug Discovery
Jeffery Engelhardt, DVM, Ph.D.
VP, Pathology
Joel Edwards
Holly Kordasiewicz

Jeffery Engelhardt, DVM, Ph.D.

VP, Pathology
Joel Edwards
VP, Corporate & Commercial Operations
Joel Ekstrom
Jeffery Engelhardt

Joel Edwards

VP, Corporate & Commercial Operations
Joel Ekstrom, MBA
VP, IT
John Su
Joel Edwards

Joel Ekstrom, MBA

VP, IT
John Su, Ph.D.
VP, Biometrics
Kameel Farag
Joel Ekstrom

John Su, Ph.D.

VP, Biometrics
Kameel Farag
VP, Finance
Ken Newman
John Su

Kameel Farag

VP, Finance
Ken Newman, M.D., MBA
VP, Clinical Development
Kristina Bowyer
Kameel Farag

Ken Newman, M.D., MBA

VP, Clinical Development
Kristina Bowyer
VP, Patient Advocacy
Leo Sahelijo
Ken Newman

Kristina Bowyer

VP, Patient Advocacy
Leo Sahelijo, M.D.
VP, Translational Medicine
Matt Buck
Kristina Bowyer

Leo Sahelijo, M.D.

VP, Translational Medicine
Matt Buck, J.D.
VP, Regulatory Affairs
Michael McCaleb
Leo Sahelijo

Matt Buck, J.D.

VP, Regulatory Affairs
Michael McCaleb, Ph.D.
VP, Clinical Development
Paul Goldberg
Matt Buck

Michael McCaleb, Ph.D.

VP, Clinical Development
Paul Goldberg, M.B., Ch.B., Ph.D.
VP, Clinical Development
Punit Seth
Michael McCaleb

Paul Goldberg, M.B., Ch.B., Ph.D.

VP, Clinical Development
Punit Seth, Ph.D.
VP, Med Chemistry
Rob MacLeod
Paul Goldberg

Punit Seth, Ph.D.

VP, Med Chemistry
Rob MacLeod, Ph.D.
VP, Oncology
Roger Lane
Punit Seth

Rob MacLeod, Ph.D.

VP, Oncology
Roger Lane, M.D., MPH
VP, Clinical Development
Roslyn Patterson
Rob MacLeod

Roger Lane, M.D., MPH

VP, Clinical Development
Roslyn Patterson, MBA
VP, Corporate Communications
Sam Tsimikas
Roger Lane

Roslyn Patterson, MBA

VP, Corporate Communications

760-603-4679
RPatterson@ionisph.com

Sam Tsimikas, M.D.
VP, Clin Dev & CV Franchise Leader
Sanjay Bhanot
Roslyn Patterson

Sam Tsimikas, M.D.

VP, Clin Dev & CV Franchise Leader
Sanjay Bhanot, M.D., Ph.D.
CMO & Franchise Leader: Cardiometabolic Diseases
Scott Henry
Sam Tsimikas

Sanjay Bhanot, M.D., Ph.D.

CMO & Franchise Leader: Cardiometabolic Diseases
Scott Henry, Ph.D.
VP, Preclinical Development
Shannon Devers
Sanjay Bhanot

Scott Henry, Ph.D.

VP, Preclinical Development
Shannon Devers
VP, Human Resources
Shuling Guo
Scott Henry

Shannon Devers

VP, Human Resources
Shuling Guo, Ph.D.
VP, Drug Discovery
Wade Walke
Shannon Devers

Shuling Guo, Ph.D.

VP, Drug Discovery
Wade Walke, Ph.D.
VP, Investor Relations
Shuling Guo

Wade Walke, Ph.D.

VP, Investor Relations

760-603-2741
WWalke@ionisph.com

Stanley T. Crooke, M.D., Ph.D.
Executive Chairman of the Board
Brett P. Monia

Stanley T. Crooke, M.D., Ph.D.

Executive Chairman of the Board

Dr. Crooke is the founder and executive chairman of the Board at Ionis Pharmaceuticals. Under his leadership, Ionis pioneered development of the revolutionary antisense technology platform and created one of the largest, most advanced pipelines in the biotechnology industry. Today, Ionis has more than 40 medicines in development.

Prior to founding Ionis, Dr. Crooke was head of R&D at SmithKline, where he was involved in commercializing numerous drugs in broad therapeutic areas and later assumed responsibility for worldwide R&D at SmithKline Beckman. At Bristol-Myers, he established the first broad anticancer program, bringing nine drugs to the market in five years.

He has led the development of more than 20 marketed drugs and supported the creation and growth of several companies based on Ionis’ antisense technology. Commercialization of SPINRAZA® (nusinersen), the global foundation of care treatment for spinal muscular atrophy, and TEGSEDI™ (inotersen), the world’s first RNA-targeting subcutaneous injection to treat polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults, are recent examples of Ionis’ transformational therapies being delivered to patients in need.

Dr. Crooke is a recipient of the Massry Prize, recognizing his pioneering work in RNA-targeted therapeutics, the Oligonucleotide Therapeutics Society Lifetime Achievement Award, the American Chemical Society’s E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Prix Galien Best Biotechnology Award for Spinraza, the Scrip Lifetime Achievement Award, and BIO’s Helix Award for the most important innovation, and other awards.

Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine and has been an active scientist throughout his career. He has published nearly 500 scientific publications, edited more than 20 books, and has numerous patents.

Brett P. Monia, Ph.D.
Chief Executive Officer
Spencer R. Berthelsen
Stanley T. Crooke

Brett P. Monia, Ph.D.

Chief Executive Officer

Dr. Monia is the chief executive officer and a founding member of Ionis Pharmaceuticals. His contributions at Ionis include research into the medicinal chemistry and mechanisms of action of RNA-targeting modalities to treat human diseases, most notably antisense-based therapeutic strategies. Dr. Monia has extensive experience across a range of therapeutic areas, including oncology, metabolic disease, inflammation, neurological disease and cardiovascular disease, which have resulted in a broad range of successful clinical achievements and in marketing approvals for new medicines.

Dr. Monia has published more than 200 primary research manuscripts, reviews and book chapters, and is an inventor on more than 100 issued patents. He serves as a senior editor for the journal Nucleic Acid Therapeutics, is on the Board of Directors for Dynacure, and has served as president of the Oligonucleotide Therapeutics Society (OTS). Dr. Monia is also an adjunct professor of biology at San Diego State University where he lectures at the graduate level on pharmacology.

Dr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and B.S. degrees in Molecular Biology and Analytical Chemistry at Stockton State College in Pomona, New Jersey.

Spencer R. Berthelsen, M.D.
Managing Director, Kelsey-Seybold Clinic, Ret.
Breaux Castleman
Brett P. Monia

Spencer R. Berthelsen, M.D.

Managing Director, Kelsey-Seybold Clinic, Ret.

Dr. Berthelsen has served as a director of Ionis since May 2002. Since 1980, he has practiced Internal Medicine with the Kelsey Seybold Clinic, a 400-physician medical group based in the Texas Medical Center in Houston. Dr. Berthelsen has served in various senior leadership positions at Kelsey Seybold, including chairman of the Department of Internal Medicine, medical director and managing director. He served as chairman of their Board of Directors from October 2001 through April 2016. He has served as a clinical professor of Medicine at Baylor College of Medicine and the University of Texas Health Science Center of Houston. Dr. Berthelsen served on the board of the Texas Academy of Internal Medicine in the past and the Caremark National Pharmacy and Therapeutics Committee from 1999 through 2005.

Breaux Castleman
President and Chief Executive Officer, Syntiro Healthcare Services, Inc.
Michael Hayden
Spencer R. Berthelsen

Breaux Castleman

President and Chief Executive Officer, Syntiro Healthcare Services, Inc.

Mr. Castleman has served as a director of Ionis since June 2013. Since August 2001, Mr. Castleman has been president and chief executive officer of Syntiro Healthcare Services, Inc., a healthcare investment company, which sold its operations as a service provider of integrated care management and disease management. Mr. Castleman was a director of USMD Holdings, Inc., a physician-led integrated healthcare system, from September 2009 until October 2016 and was a director of MELA Sciences, Inc., a medical device company, from 2003 until 2011.

Michael Hayden, C.M. O.B.C. M.B. Ch.B. Ph.D. F.R.C.P.(C) F.R.S.C.
Killam Professor at the University of British Columbia and the Director of the Translational Laboratory in Genetic Medicine
Joan E. Herman
Breaux Castleman

Michael Hayden, C.M. O.B.C. M.B. Ch.B. Ph.D. F.R.C.P.(C) F.R.S.C.

Killam Professor at the University of British Columbia and the Director of the Translational Laboratory in Genetic Medicine

Dr. Michael Hayden is a Killam Professor at the University of British Columbia and the director of the Translational Laboratory in Genetic Medicine at the National University of Singapore and the Agency for Science, Technology and Research (A*STAR). From 2012 to 2017, he served as president of Global R&D and chief scientific officer at Teva Pharmaceutical Industries Ltd. Dr. Hayden built and transformed research and development at Teva to become a highly productive research engine and was instrumental in the approval of approximately 30 new products.

Dr. Hayden has founded three biotechnology companies and has been the recipient of numerous prestigious honors and awards including being inducted into the Canadian Medical Hall of Fame, receiving the July 2012 Diamond Jubilee Medal, on behalf of HRH Queen Elisabeth II and the Margolese National Brain Disorder Prize, awarded to Canadians who have made outstanding contributions to the treatment, amelioration, or cure of brain diseases. He’s also received the Canada Gairdner Wightman award for his outstanding leadership in medicine and medical science as a physician-scientist. Dr. Hayden was awarded the Order of Canada, the Order of British Columbia, named Canada’s Health Researcher of the Year by Canadian Institutes of Health Research, and has received the Prix Galien for his contribution to Canadian pharmaceutical research. Most recently, Dr. Hayden was named one of the 50 Canadians born in the 20th century who have changed the world.

Joan E. Herman
President and CEO, Herman and Associates
Joseph Klein
Michael Hayden

Joan E. Herman

President and CEO, Herman and Associates

Ms. Herman has served as a director of Ionis since June 2019. She is currently President and CEO of Herman & Associates, a management consulting firm that specializes in advising private equity firms investing in healthcare. She has deep experience leading healthcare and payor companies, serving in several executive positions at Anthem (formerly WellPoint), including as president and CEO of the Consumer Business unit, president and CEO of the Specialty, Senior and State Sponsored Business and group president, Senior and Specialty Businesses. Ms. Herman also served as a senior vice president of Phoenix Life Insurance Company. Ms. Herman currently serves on the board of directors for Encompass Health (formerly HealthSouth) and previously served on the boards of both Convergys and AARP Services, Inc. She has earned degrees from Barnard College, Columbia University (summa cum laude, BS Mathematics), Yale University (MS) and Western New England University (MBA).

Joseph Klein, III
Managing Director, Gauss Capital Advisors, LLC
Joseph Loscalzo
Joan E. Herman

Joseph Klein, III

Managing Director, Gauss Capital Advisors, LLC

Mr. Klein has served as a director of Ionis since December 2005. Mr. Klein is currently managing director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008, Mr. Klein also served as a venture partner of Red Abbey Venture Partners, L.P., a life science private equity fund. From September 2001 to September 2002, Mr. Klein was a venture partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as vice president, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems. For over nine years from 1989 to 1998, Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. Mr. Klein serves on the board of directors of The Prospector Funds, Inc., an SEC Registered Investment Company that manages two no-load mutual funds. Mr. Klein also serves on the boards of private and non-profit entities.

Joseph Loscalzo, M.D., Ph.D.
Head of Department of Medicine and Physician-in-Chief, Brigham & Woman's Hospital, Harvard Medical School
Frederick T. Muto
Joseph Klein

Joseph Loscalzo, M.D., Ph.D.

Head of Department of Medicine and Physician-in-Chief, Brigham & Woman's Hospital, Harvard Medical School

Dr. Loscalzo is Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, chairman of the Department of Medicine, and physician-in-chief at Brigham and Women’s Hospital. Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. His clinical training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine. Post-training, Dr. Loscalzo joined the Harvard faculty and staff at Brigham and Women’s Hospital in 1984. He rose to the rank of associate professor of Medicine, Chief of Cardiology at the West Roxbury Veterans Administration Medical Center, and director of the Center for Research in Thrombolysis at Brigham and Women’s Hospital. He joined the faculty of Boston University in 1994, first as Chief of Cardiology and, in 1997, Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. He returned to Harvard and Brigham and Women’s Hospital in 2005. He currently serves on the board of directors of Leap Therapeutics, Inc., a publicly held biopharmaceutical company.

Frederick T. Muto, Esq.
Senior Counsel, Cooley LLP
B. Lynne Parshall
Joseph Loscalzo

Frederick T. Muto, Esq.

Senior Counsel, Cooley LLP

Mr. Muto has served as a director of Ionis since March 2001. Mr. Muto joined the law firm of Cooley LLP, outside counsel to Ionis, in 1980, became a partner in 1986 and Senior Counsel in 2018. He is a founding Senior Counsel of Cooley LLP’s San Diego office and was Chair of the firm’s Business Department for a number of years.

B. Lynne Parshall, Esq.
Senior Strategic Advisor, Ionis
Peter N. Reikes
Frederick T. Muto

B. Lynne Parshall, Esq.

Senior Strategic Advisor, Ionis

Ms. Parshall has served on the Ionis board since September 2000 and as a senior strategic advisor to Ionis since January 2018. Previously she served as our chief operating officer from December 2007 through December 2017 and as chief financial officer from June 1994 through December 2012. She also served as Ionis’ corporate secretary through 2014, and has served with the company in various executive roles since November 1991. Prior to joining Ionis, Ms. Parshall practiced law at Cooley LLP, outside counsel to Ionis, where she was a partner from 1986 to 1991. Ms. Parshall is a member of the American and California bar associations. Ms. Parshall serves on the board of directors of Cytokinetcs Inc. and Akcea Therapeutics, Inc.

Peter N. Reikes
Vice Chairman, Investment Banking Division, Stifel, Nicolaus & Company, Inc.
Joseph H. Wender
B. Lynne Parshall

Peter N. Reikes

Vice Chairman, Investment Banking Division, Stifel, Nicolaus & Company, Inc.

Peter N. Reikes is a vice chairman in the Investment Banking Division at Stifel, Nicolaus & Company, Incorporated, which he joined in late 2010. Over the course of his more than 30-year career in investment banking, Mr. Reikes has completed a wide range of financing and merger and acquisition transactions for companies in the life sciences, medical technology, and healthcare services sectors. Prior to joining Stifel, Nicolaus, he spent eleven years at Cowen and Company, LLC, where he was vice chairman and head of Healthcare Investment Banking, and over fourteen years at PaineWebber Incorporated, where he was a managing director and head of Healthcare Investment Banking and began his career in 1985.

Mr. Reikes is a former director of Ricerca Biosciences, LLC, Biocompatibles, Ltd., and the affiliated partnership boards of Alkermes, Inc., Cephalon, Inc., Gensia, Inc., Genzyme Corporation, and Repligen Corporation, as well as the Institute for Quality Improvement of the Accreditation Association for Ambulatory Health Care. Mr. Reikes also is a director of the Heart & Soul Foundation, an organization which supports a range of community service programs in the greater New York City area. Mr. Reikes received his B.A. in Economics from the University of California at Los Angeles and his M.B.A. in Finance from The Wharton School at the University of Pennsylvania.

Joseph H. Wender
Senior Consultant, Goldman Sachs & Co.
Peter N. Reikes

Joseph H. Wender

Senior Consultant, Goldman Sachs & Co.

Mr. Wender has served as a director of Ionis since January 1994. Mr. Wender began with Goldman, Sachs & Co. in 1971 and became a general partner of that firm in 1982, where he headed the Financial Institutions Group for over a decade. Since January 2008, he has been a senior consultant to Goldman Sachs & Co. He is also an Independent Trustee of the Schwab Family of Funds and Director of Grandpoint Capital, a bank holding company. Mr. Wender also is co-CEO and minority partner, with his wife, of Colgin Cellars. Since March 2014, Mr. Wender has been a director, and is currently lead director, of Outfront Media, lessors of advertising space on out-of-home advertising structures.

Maximizing the value of each medicine

Because antisense therapies can treat the rarest of diseases as well as those that affect millions of people, we pursue the optimal development and commercialization path to maximize the success of each medicine and deliver it most efficiently to patients. In some cases, we form strategic partnerships with pharmaceutical companies. We also create affiliate companies that are responsible for the commercialization of some of our medicines. Akcea is the first of our commercial affiliates.

Akcea Logo

Akcea Therapeutics, Inc.

Akcea is a biopharmaceutical company we established to focus on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs, licensed from us, including TEGSEDI™ (inotersen), WAYLIVRA®(volanesorsen), AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx and AKCEA-TTR-LRx, with the potential to treat multiple diseases. All drugs were discovered by Ionis and are based on Ionis’ proprietary antisense technology.

Contact Us

For questions or to request information, please contact us.

A history of advancing science

Ionis: A history of advancing science

The Field of Antisense Oligoneucleotides is born - Antisense RNA is first used to inhibit protein production
Ionis IPO
First proven in vivo antisense activities
Chimeric (gapmer) antisense medicines with proven pharmacological advantages demonstrated
First Antisense Drug Reaches the Market – Vitravene (fomivirsen) is approved as a treatment for CMV-induced retinitis in immunocompromised patients with AIDS
Ionis initiates cardiovascular program
Selection of constrained ethyl (cET) as generation 2.5 chemistry, providing enhanced potency and broad distribution to multiple tissues.
Akcea, Ionis’ first commercial affiliate, founded
Approval of SPINRAZA
Approval for TEGSEDI
1978
1989
1991
1992
1993
1995
1998
1999
2000
2003
2010
2013
2014
2015
2016
2017
2018
2019
First Generation Chemistry chosen – Antisense oligonucleotides with phosphorothioate (PS) substitutions are more stable and able to distribute broadly throughout the body, making selected RNase H1 based antisense as a key mechanism
Ionis founded by Stanley T. Crooke, M.D., Ph.D.
Classification of potential antisense mechanisms
2'-0-methoxyethyl (2'MOE) discovered, making antisense medicines more RNA-like, with greater affinity for targets, greater potency
RNase H1 characterized enabling design of optimized antisense therapies
Human genome project completed, revolutionizing the diagnosis and treatment of human diseases
Ionis initiates neurological disease program
Approval of KYNAMRO
Demonstrated increased uptake of therapies in the liver by linking a GalNAc molecule to the antisense oligonucleotide
Further identification of mechanisms of cell uptake and intracellular distribution
Akcea IPO
1978
The Field of Antisense Oligoneucleotides is born - Antisense RNA is first used to inhibit protein production
1989
First Generation Chemistry chosen – Antisense oligonucleotides with phosphorothioate (PS) substitutions are more stable and able to distribute broadly throughout the body, making selected RNase H1 based antisense as a key mechanism
Ionis founded by Stanley T. Crooke, M.D., Ph.D.
1991
Ionis IPO
1992
Classification of potential antisense mechanisms
1993
First proven in vivo antisense activities
Chimeric (gapmer) antisense medicines with proven pharmacological advantages demonstrated
1995
2'-0-methoxyethyl (2'MOE) discovered, making antisense medicines more RNA-like, with greater affinity for targets, greater potency
1998
First Antisense Drug Reaches the Market – Vitravene (fomivirsen) is approved as a treatment for CMV-induced retinitis in immunocompromised patients with AIDS
1999
RNase H1 characterized enabling design of optimized antisense therapies
2000
Ionis initiates cardiovascular program
2003
Human genome project completed, revolutionizing the diagnosis and treatment of human diseases
Ionis initiates neurological disease program
2010
Selection of constrained ethyl (cET) as generation 2.5 chemistry, providing enhanced potency and broad distribution to multiple tissues.
2013
Approval of KYNAMRO
Demonstrated increased uptake of therapies in the liver by linking a GalNAc molecule to the antisense oligonucleotide
2014
Akcea, Ionis’ first commercial affiliate, founded
2015
Further identification of mechanisms of cell uptake and intracellular distribution
2016
Approval of SPINRAZA
2017
Akcea IPO
2018
Approval for TEGSEDI

Pioneering a more efficient way to treat disease

Bridging genomic discovery to life-saving therapies, we believe antisense technology is the key to treating the untreatable.

Fred and Lynne’s story

Fred and Lynne have been married for 40+ years. When talking about Fred’s illness, Lynne often looks back to when she said, “I do,” and thinks about how she had no idea at the time what “in sickness and in health” would really mean.